The molecular pathogenesis of FTC is believed to begin with point mutations that lead to dysregulation of the phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway. The gene discussed is PIK3CA; the disease is thyroid cancer, nonmedullary, 2.